



## Novel Biomarkers: Validity, Evaluation and Biological Roles for Breast Cancer

Guest Editors:

**Prof. Trine Tramm**

Department of Pathology, Aarhus University Hospital, Palle Juul-Jensens Boulevard, Aarhus N, Denmark

**Prof. Anne Vibeke Lænkholm**

1. Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark  
2. Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark

Deadline for manuscript submissions:

**closed (30 April 2022)**

### Message from the Guest Editors

Dear colleagues,

The routine work of the surgical pathologist is rapidly changing due to breakthroughs in, e.g., molecular pathology. The diagnostic process is increasingly precise, and potential prognostic and predictive biomarkers are constantly being developed and presented to the multidisciplinary cancer team.

In order to attain clinical utility, it is, however, of utmost importance to secure not only clinical validity with significant results from clinical studies supporting benefit in specific patient groups in terms of overall or disease-free survival, but also analytical validity securing reproducible and robust analytical methods encompassing, e.g., conventional histopathology, immunohistochemical stainings, and molecular pathology.

This Special Issue of *Cancers* will focus on novel diagnostic, prognostic, and predictive markers in breast cancer, including the use of digital solutions to evaluate biomarker expression. The issue will further focus on the necessity to secure the analytical validity for a biomarker to be applicable in the clinical setting. The issue will encompass new research articles and timely reviews.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)